Skip to main content
OpenTrials
Completed

NCT Number: NCT02407353

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

This is phase 1 investigator-and-subject blind, sponsor open, randomized, placebo controlled, parallel study in healthy subjects to evaluate the pharmacodynamics effect of single oral doses of PF-06648671 on CSF Aβ concentrations using serial CSF sampling methodology.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

California Clinical Trials Medical Group, Inc., Glendale, California, United States

Loading trial locations.

About this study

This study is investigator-and-subject blind, sponsor open, randomized, placebo-controlled, parallel study in healthy subjects to evaluate central (CSF) and peripheral (plasma) pharmacodynamics effects (Abeta) over 36 hours post single doses of PF-06648671. Two cohorts will be run in sequential. the first cohort is to evaluate the Abeta effect at top dose of 300 mg PF-06648671 and second cohort is to evaluate the Abeta effect at top dose (if more subjects are required) and/or 1-2 lower doses

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and/or female subjects of non childbearing potential
  • BMI of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lbs)
  • Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study.

Exclusion criteria

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated asymptomatic, seasonal allergies at the time of dosing)
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer)
  • Subjects with a history of significant active bleeding, coagulation disorder or clinically significant finding on prothrombin time/ partial thromboplastin time/International Normalized Ratio (PT/PTT/INR) at Screening
  • Subjects with lower spinal malformations (on physical examination), local spinal infection, or other abnormalities that would exclude puncture (LP)
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study

Treatment and study plan

PF-06648671

Drug

Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses

Placebo

Drug

Placebo which will be dosed as oral suspension, single doses to match PF-06648671

Primary outcomes

  1. CSF Aβ40 and Aβ42 concentration at maximum change from baseline

    Time frame: 0-36 hours postdose

Secondary outcomes

  1. Number of participants with AEs and SAEs

    Time frame: 0-2 weeks

    Counts of participants who have TEAEs, defined as newly occuring or worsening after first dose. Relatedness to PF-06648671 will be assessed by the investigator (Yes/No). Participants with multiple occurrence of an AE within a category will be counted once within the category

  2. supine vital sign

    Time frame: 0-2 weeks

    Measurement of supine vital signs

  3. Electrocardiogram (ECG)

    Time frame: 0-2 weeks

    Measurement of standard 12-lead ECG (single)

  4. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0-72 hours postdose

  5. Area Under the Curve from Time Zero to Last Quantifiable Plasma Concentration (AUClast)

    Time frame: 0-72 hours postdose

  6. Area Under the Curve From Time Zero to Extrapolated Infinite Time in Plasma (AUCinf)

    Time frame: 0-72 hours postdose

  7. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0-72 hours postdose

  8. Plasma Decay Half-life (t1/2)

    Time frame: 0-72 hours postdose

  9. Apparent Oral Clearance (CL/F)

    Time frame: 0-72 hours postdose

  10. Apparent Volume of Distribution (Vz/F))

    Time frame: 0-72 hours postdose

  11. Maximum Observed CSF Concentration (CSF Cmax)

    Time frame: 0-36 hours postdose

  12. Area Under the Curve from Time Zero to Last Quantifiable Concentration in CSF (CSF AUClast)

    Time frame: 0-36 hours postdose

  13. Area Under the Curve From Time Zero to Extrapolated Infinite Time in CSF (CSF AUCinf)

    Time frame: 0-36 hours postdose

  14. CSF Decay Half-life (CSF t1/2)

    Time frame: 0-36 hours postdose

  15. Plasma Aβ40, Aβ42 and Aβtotal

    Time frame: 0-72 hours postdose

    Plasma Aβ40, Aβ42 and Aβtotal if possible

  16. CSF Aβ37, Aβ38 and Aβtotal Concentration

    Time frame: 0-36 hours postdose

  17. Number of participants with lab test values of potential clinical importance

    Time frame: 0-2 weeks

    Pre-defined criteria were established for each lab test to identify potential clinical importance

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 2, 2015
Registry last updated
Mar 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.